Azopharma has established relationships with iQ Synthesis and Cyanta Drug Development, expanding its Product Development Group. Phil Meeks, chief executive officer of the Azopharma Product Development Group of companies, said, “These two additions, combined with our four current companies, will round out our service offering portfolio and enhance our position as a major resource in the global contract product development arena. We are now poised to capitalize on the emerging trends transfor...